{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:51:08Z","timestamp":1788904268916,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The role of excess androgen in ovarian reserve remains unclear in patients with polycystic ovary syndrome (PCOS). Our study highlights the associations of serum androgen levels and ovarian reserve markers in PCOS and non-PCOS women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Totally 584 menstrual abnormalities women of 20-45 years were retrospectively evaluated at the Beijing Obstetrics and Gynecology Hospital between January 2021 to October 2021. The enrolled patients were classified into two groups: the PCOS group (n=288) and the non-PCOS group (n=296) based on the Rotterdam consensus for PCOS diagnosis. The serum androgens, including testosterone (T), free testosterone (FT, calculated), bioavailable testosterone (Bio-T, calculated), androstenedione (A2), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS) were assessed with an in-house developed liquid chromatography tandem mass spectrometry (LC-MS\/MS) method. The associations between the serum androgens and the hormone markers commonly used for evaluating ovarian reserve function, such as anti-mullerian hormone (AMH) and the ratio of luteinizing hormone (LH)\/follicle stimulating hormone (FSH) were explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The serum T, FT, Bio-T, A2, DHT, DHEA, DHEAS, AMH and LH\/FSH of the PCOS group were 51.7 \u00b1 23.2 ng\/dL\/mL, 8.5 \u00b1 5.0 pg\/mL, 210.1 \u00b1 127.7 pg\/mL, 1.9 \u00b1 0.8 ng\/mL, 0.2 \u00b1 0.1 ng\/mL, 6.4 \u00b1 4.2 ng\/mL, 2431.0 \u00b1 1030.7 ng\/mL, 6.7 \u00b1 3.8 ng\/mL, and 1.8 \u00b1 1.4 respectively, which were significantly higher than those in the non-PCOS group (<jats:italic>p<\/jats:italic>&amp;lt;0.05). In the group of PCOS patients, T and A2 levels were positively associated with AMH in both multivariate linear regression analysis and Pearson\u2019s correlation analysis. Similar but weaker associations were observed in the non-PCOS patients. In the PCOS patients with hyperandrogenemia (HA), the AMH level was significantly higher in the subjects with T increased than in the subjects with non-T androgen(s) increased (A2, DHT, DHEA or DHEAS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The serum androgen levels are positively associated with ovarian reserve markers in both of the PCOS and the non-PCOS patients in our study. In the PCOS group, the highest AMH level was observed in the subjects with the T elevation subgroup, suggesting that T is more closely related with the increase of AMH when compared with other androgens investigated.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.881740","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T04:54:42Z","timestamp":1654750482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Divergent Associations Between Serum Androgens and Ovarian Reserve Markers Revealed in Patients With Polycystic Ovary Syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Youran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic Ovary Syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13753","article-title":"Pharmacological and Surgical Treatment of Nonreproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews","volume":"89","author":"Tay","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.02.027","article-title":"Ovarian Reserve Testing: A User\u2019s Guide","volume":"217","author":"Tal","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1055\/a-1079-5342","article-title":"Insulin Resistance and Free Androgen as Predictors for Ovarian Hyperstimulation Syndrome in Non-PCOS Women","volume":"52","author":"Nikbakht","year":"2020","journal-title":"Horm Metab Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0178","article-title":"Positions Statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4158\/EP15748.DSCPT2","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices In the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 2","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1365.011","article-title":"Ovarian and Adrenal Hyperandrogenism","volume":"1092","author":"Carmina","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, Phenotype and Cardiometabolic Risk of Polycystic Ovary Syndrome Under Different Diagnostic Criteria","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum Reprod"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23539","article-title":"Simultaneous Quantitation of Four Androgens and 17-Hydroxyprogesterone in Polycystic Ovarian Syndrome Patients by LC-MS\/MS","volume":"34","author":"Cao","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4158\/EP15748.DSC","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices In the Evaluation and Treatment of Polycystic Ovary Syndrome\u2013Part 1","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/b978-0-12-800094-6.00002-9","article-title":"Free Testosterone: Clinical Utility and Important Analytical Aspects of Measurement","volume":"63","author":"Shea","year":"2014","journal-title":"Adv Clin Chem"},{"key":"B16","article-title":"Comparison Of Free Androgen Index In Polycystic Ovary Syndrome And Non-Polycystic Ovary Syndrome Infertile Patients","volume":"33","author":"Khattak","year":"2021","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.06.009","article-title":"New Biomarkers for Diagnosis and Management of Polycystic Ovary Syndrome","volume":"471","author":"Karakas","year":"2017","journal-title":"Clin Chim Acta"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1754","article-title":"Reproductive and Metabolic Phenotype of a Mouse Model of PCOS","volume":"153","author":"van Houten","year":"2012","journal-title":"Endocrinology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmw027","article-title":"Interactions Between Androgens, FSH, Anti-M\u00fcllerian Hormone and Estradiol During Folliculogenesis in the Human Normal and Polycystic Ovary","volume":"22","author":"Dewailly","year":"2016","journal-title":"Hum Reprod Update"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20210728-01683","article-title":"[Analysis of Clinical Features and Etiological Diagnostic Indices of Reproductive Age Women With Hyperandrogenism]","volume":"102","author":"Zhang","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7555\/JBR.32.20170136","article-title":"Follicular Hyperandrogenism and Insulin Resistance in Polycystic Ovary Syndrome Patients With Normal Circulating Testosterone Levels","volume":"32","author":"Li","year":"2017","journal-title":"J BioMed Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.07.008","article-title":"Adrenocortical Hyperresponsiveness to Corticotropin in Polycystic Ovary Syndrome Patients With Adrenal Androgen Excess","volume":"81","author":"Moran","year":"2004","journal-title":"Fertil Steril"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02256.x","article-title":"Prevalence of Adrenal Androgen Excess in Patients With the Polycystic Ovary Syndrome (PCOS)","volume":"62","author":"Kumar","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","article-title":"Insuffisance Ovarienne Pr\u00e9matur\u00e9e [Premature Ovarian Failure]","volume":"29","author":"Barbarino-Monnier","year":"2000","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa513","article-title":"Anti-M\u00fcllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function","volume":"105","author":"Moolhuijsen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bpobgyn.2018.05.005","article-title":"Natural History of Ovarian Function Including Assessment of Ovarian Reserve and Premature Ovarian Failure","volume":"55","author":"Lew","year":"2019","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt062","article-title":"The Physiology and Clinical Utility of Anti-Mullerian Hormone in Women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12886","article-title":"Fluctuations in Anti-M\u00fcllerian Hormone Levels Throughout the Menstrual Cycle Parallel Fluctuations in the Antral Follicle Count: A Cohort Study","volume":"95","author":"Depmann","year":"2016","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dml017","article-title":"The Origins and Sequelae of Abnormal Neuroendocrine Function in Polycystic Ovary Syndrome","volume":"12","author":"Blank","year":"2006","journal-title":"Hum Reprod Update"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13934","article-title":"Exploration of the Role of Anti-Mullerian Hormone and LH\/FSH Ratio in Diagnosis of Polycystic Ovary Syndrome","volume":"90","author":"Le","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.09.134","article-title":"Testing and Interpreting Measures of Ovarian Reserve: A Committee Opinion","volume":"114","year":"2020","journal-title":"Fertil Steril"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.10.6079","article-title":"A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000341679","article-title":"Pathophysiology of Polycystic Ovary Syndrome: The Role of Hyperandrogenism","volume":"40","author":"Catteau-Jonard","year":"2013","journal-title":"Front Horm Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.fertnstert.2011.11.029","article-title":"Does PCOS Have Developmental Origins","volume":"97","author":"Franks","year":"2012","journal-title":"Fertil Steril"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00641","article-title":"Role of Anti-M\u00fcllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome","volume":"11","author":"Dewailly","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0015","article-title":"Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome","volume":"24","author":"De Leo","year":"2003","journal-title":"Endocr Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1038\/s41598-021-85915-x","article-title":"Serum Testosterone Levels are Positively Associated With Serum Anti-Mullerian Hormone Levels in Infertile Women","volume":"11","author":"Lin","year":"2021","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-017-0326-3","article-title":"The Effect of Dehydroepiandrosterone Supplementation on Ovarian Response is Associated With Androgen Receptor in Diminished Ovarian Reserve Women","volume":"10","author":"Hu","year":"2017","journal-title":"J Ovarian Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0334","article-title":"Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-M\u00fcllerian Hormone Concentrations Aggregate With the Markers of Hyperandrogenism","volume":"95","author":"Dewailly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des460","article-title":"Loss of LH-Induced Down-Regulation of Anti-M\u00fcllerian Hormone Receptor Expression may Contribute to Anovulation in Women With Polycystic Ovary Syndrome","volume":"28","author":"Pierre","year":"2013","journal-title":"Hum Reprod"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000445","article-title":"Anti-M\u00fcllerian Hormone in the Pathophysiology and Diagnosis of Polycystic Ovarian Syndrome","volume":"25","author":"Dumont","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mce.2003.09.007","article-title":"AMH\/MIS: What We Know Already About the Gene, the Protein and its Regulation","volume":"211","author":"Rey","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12902-020-00569-6","article-title":"Role of Anti-M\u00fcllerian Hormone and Testosterone in Follicular Growth: A Cross-Sectional Study","volume":"20","author":"Lv","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3436","article-title":"Effects of Testosterone on the Expression Levels of AMH, VEGF and HIF-1\u4f2a in Mouse Granulosa Cells","volume":"12","author":"Zhang","year":"2016","journal-title":"Exp Ther Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.881740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T04:54:47Z","timestamp":1654750487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.881740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":44,"alternative-id":["10.3389\/fendo.2022.881740"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.881740","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"881740"}}